Many risk genes interact synergistically to produce schizophrenia and many neurotransmitter interactions have been implicated. We have developed a circuitbased framework for understanding gene and neurotransmitter interactions. NMDAR hypofunction has been implicated in schizophrenia because NMDAR antagonists reproduce symptoms of the disease. One action of antagonists is to reduce the excitation of fastspiking interneurons, resulting in disinhibition of pyramidal cells. Overactive pyramidal cells, notably those in the hippocampus, can drive a hyperdopaminergic state that produces psychosis. Additional aspects of interneuron function can be understood in this framework, as follows. (i) In animal models, NMDAR antagonists reduce parvalbumin and GAD67, as found in schizophrenia. These changes produce further disinhibition and can be viewed as the aberrant response of a homeostatic system having a faulty activity sensor (the NMDAR). (ii) Disinhibition decreases the power of gamma oscillation and might thereby produce negative and cognitive symptoms. (iii) Nicotine enhances the output of interneurons, and might thereby contribute to its therapeutic effect in schizophrenia.
Introduction
Schizophrenia affects nearly 1% of the population [1] . Clinically, the disorder is characterized by positive symptoms (psychosis, hallucinations and paranoia), negative symptoms (flat affect, poor attention, lack of motivation and deficits in social function) and cognitive deficits. Population, family and twin studies indicate that schizophrenia is highly heritable, but no single gene has a strong effect. Rather, the disorder is due to the synergistic interaction of multiple genes and environmental factors [2] . Recent association and linkage studies have identified over a dozen risk genes for schizophrenia [3] . Another line of research has focused on neurotransmitter systems and, again, the evidence, rather than identifying a single factor, points to abnormalities in multiple systems: glutamate, GABA, dopamine and acetylcholine have all been implicated. There is therefore a strong need for an integrative approach to explain how multiple genes and neurotransmitters can interact in a synergistic way to produce the disorder. In this review, we will describe neural circuitry that provides a framework for understanding many of these interactions. Our description builds on several previous integrative approaches [4, 5] but extends that work in several ways, notably by suggesting a systemslevel explanation for the changes in GABAergic interneurons that occur in schizophrenia.
GABA hypofunction
Studies of postmortem brain tissue have provided strong evidence that the GABAergic system is impaired in schizophrenia (this is termed hypofunction). These studies showed reductions in the concentration of cortical GABA [6] and the activity of glutamate decarboxylase (GAD) [7] , the enzyme that synthesizes GABA. These observations were confirmed and extended in subsequent studies showing alteration in several presynaptic components of the GABAergic system [8] [9] [10] [11] [12] [13] [14] . The GABA deficit does not affect all classes of cortical GABAergic interneurons equally [15] , but is restricted mainly to the basket and chandelier type of interneurons [16, 17] . These two types have fast-spiking properties, contain the Ca 2+ -binding protein parvalbumin, and synapse on the perisomatic region of pyramidal cells. Because they target the spike-initiating region of neurons, fast-spiking interneurons are thought to have a key role in 
